BR, et al. Elagolix treatment for up to 12 months in women with heavy menstrual bleeding and uterine leiomyomas. Obstet Gynecol 2020;135. The authors provided this information as a supplement to their article.

(Abstracted from Obstet Gynecol 2020;135:1313–1326) Uterine leiomyomas affect up to 80% of reproductive-age women and are the most common benign neoplasm of the uterus. A variety of symptoms occur in approximately half of these women; the most common is heavy menstrual bleeding (HMB), which can result in anemia.